Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Echinococcus granulosus | caspase 2 | 0.0447 | 0.2771 | 0.6304 |
Loa Loa (eye worm) | hypothetical protein | 0.0447 | 0.2771 | 0.2771 |
Echinococcus granulosus | integrin alpha ps | 0.0336 | 0.1643 | 0.3108 |
Schistosoma mansoni | caspase-3 (C14 family) | 0.0228 | 0.0546 | 0.0931 |
Echinococcus multilocularis | integrin alpha ps | 0.0336 | 0.1643 | 0.3108 |
Echinococcus granulosus | integrin alpha 3 | 0.0575 | 0.4076 | 1 |
Schistosoma mansoni | caspase-7 (C14 family) | 0.0228 | 0.0546 | 0.0931 |
Schistosoma mansoni | caspase-7 (C14 family) | 0.0447 | 0.2771 | 0.4728 |
Onchocerca volvulus | Cell death protein 3 homolog | 0.0447 | 0.2771 | 0.5 |
Schistosoma mansoni | integrin alpha | 0.0749 | 0.586 | 1 |
Brugia malayi | Integrin alpha cytoplasmic region family protein | 0.0567 | 0.3998 | 0.3972 |
Loa Loa (eye worm) | hypothetical protein | 0.0588 | 0.4217 | 0.4217 |
Brugia malayi | Integrin alpha pat-2 precursor | 0.0749 | 0.586 | 1 |
Schistosoma mansoni | integrin alpha-ps | 0.0336 | 0.1643 | 0.2803 |
Echinococcus multilocularis | integrin alpha 3 | 0.0575 | 0.4076 | 1 |
Echinococcus multilocularis | caspase 2 | 0.0447 | 0.2771 | 0.6304 |
Loa Loa (eye worm) | hypothetical protein | 0.0567 | 0.3998 | 0.3998 |
Echinococcus multilocularis | integrin alpha ps | 0.0336 | 0.1643 | 0.3108 |
Loa Loa (eye worm) | hypothetical protein | 0.0413 | 0.2433 | 0.2433 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Change (functional) | = -48 % | Percent change in triglycerides in hypercholesterolemic rats at a dose of 100 mg/kg/day for 8 days | ChEMBL. | 14736248 |
Change (functional) | = 23 % | Percent change in high-density lipoprotein cholesterol in hypercholesterolemic rats dosed at 100 mg/kg/day for 8 days | ChEMBL. | 14736248 |
Change (functional) | = 44 % | Percent change in total plasma cholesterol in hypercholesterolemic rats dosed at 100 mg/kg/day for 8 days | ChEMBL. | 14736248 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.